• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ocuphire Pharma Inc. (Amendment)

    1/18/22 11:17:15 AM ET
    $OCUP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUP alert in real time by email
    SC 13G/A 1 p22-0150sc13ga.htm OCUPHIRE PHARMA, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 2)*
     

    Ocuphire Pharma, Inc.

    (Name of Issuer)
     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)
     

    67577R102

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 67577R102

    13G/APage 2 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Empery Asset Management, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,063,498 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,063,498 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,063,498 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 67577R102

    13G/APage 3 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Ryan M. Lane

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,063,498 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,063,498 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,063,498 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 67577R102

    13G/APage 4 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Martin D. Hoe

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,063,498 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,063,498 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,063,498 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 67577R102

    13G/APage 5 of 8 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Ocuphire Pharma, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 37000 Grand River Avenue, Suite 120, Farmington Hills, MI 48335.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to the shares of Common Stock (as defined in Item 2(d) below) of the Company:
       
      Investment Manager
       
      (i) Empery Asset Management, LP (the "Investment Manager"), with respect to the shares of Common Stock underlying the Reported Warrants (as defined below) held by the funds to which the Investment Manager serves as investment manager (the "Empery Funds").
       
      Reporting Individuals
       
      (ii) Mr. Ryan M. Lane ("Mr. Lane"), with respect to the shares of Common Stock underlying the Reported Warrants held by the Empery Funds.
       
      (iii) Mr. Martin D. Hoe ("Mr. Hoe"), with respect to the shares of Common Stock underlying the Reported Warrants held by the Empery Funds.
       
      The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the "Reporting Individuals") is a Managing Member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
     

    The address of the business office of each of the Reporting Persons is:

     

    1 Rockefeller Plaza, Suite 1205

    New York, New York 10020

     

    Item 2(c). CITIZENSHIP:
       
      Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, $0.0001 par value (the "Common Stock")

     

    Item 2(e). CUSIP NUMBER:
       
      67577R102

     

     

    CUSIP No. 67577R102

    13G/APage 6 of 8 Pages

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940,
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:    

     

    Item 4. OWNERSHIP.
       
      The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 17,300,481 shares of Common Stock issued and outstanding as of November 10, 2021, as represented in the Company’s Quarterly Report on Form 10-Q with the Securities and Exchange Commission on November 12, 2021 and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”).
       
      Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock) (the "Blockers"), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers.  Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Reported Warrants due to the Blockers.
       
      The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock underlying the Reported Warrants (subject to the Blockers) held by the Empery Funds.  Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock underlying the Reported Warrants  (subject to the Blockers) held by the Empery Funds.  The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person.  Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

     

     

    CUSIP No. 67577R102

    13G/APage 7 of 8 Pages

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 67577R102

    13G/APage 8 of 8 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: January 18, 2022  
     

     

    EMPERY ASSET MANAGEMENT, LP

      By: EMPERY AM GP, LLC, its General Partner
       
      By: /s/ Ryan M. Lane
      Name:  Ryan M. Lane
      Title:  Managing Member
       
      /s/ Ryan M. Lane
      Ryan M. Lane
       
      /s/ Martin D. Hoe
      Martin D. Hoe

     

    Get the next $OCUP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCUP

    DatePrice TargetRatingAnalyst
    11/24/2021$26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $OCUP
    Financials

    Live finance-specific insights

    See more
    • Ocuphire Pharma Announces Acquisition of Opus Genetics

      Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025 LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances remains on track for top-line data in Q1 2025 VEGA-3 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in presbyopia remains on track for top-line data in H1 2025 Company will seek a strategic partner to continue development of

      10/22/24 4:05:00 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update

      VEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025 LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution Continues Enrollment with Top-Line Data Expected in 2025 Preparatory Steps Towards Phase 2/3 with APX3330 in Diabetic Retinopathy are Ongoing Cash Position of $41.4 million Provides Runway Anticipated into mid-2025 FARMINGTON HILLS, Mich., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive e

      8/13/24 8:00:00 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

      FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. "Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™," said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire. "We have been engaged in productive dialogue with the U.S. Food and Drug Administration (FDA) with respect to our submitted Special Protocol Assessmen

      5/10/24 8:00:00 AM ET
      $OCUP
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jayagopal Ashwath bought $6,178 worth of shares (3,500 units at $1.76), increasing direct ownership by 5% to 78,500 units (SEC Form 4)

      4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)

      5/24/24 4:07:59 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magrath George bought $8,772 worth of shares (5,000 units at $1.75), increasing direct ownership by 1% to 430,000 units (SEC Form 4)

      4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)

      5/21/24 4:18:02 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schachle Joseph K bought $4,100 worth of shares (2,000 units at $2.05) (SEC Form 4)

      4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)

      3/25/24 4:44:40 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUP
    SEC Filings

    See more
    • Ocuphire Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Ocuphire Pharma, Inc. (0001228627) (Filer)

      10/22/24 5:09:12 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ocuphire Pharma Inc.

      10-Q - Ocuphire Pharma, Inc. (0001228627) (Filer)

      8/13/24 4:06:42 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocuphire Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ocuphire Pharma, Inc. (0001228627) (Filer)

      8/13/24 8:14:28 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

      The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C., Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (NASDAQ:OCUP) a clinical-stage ophthalmic biopharmaceutical company. The companies have combined under the name of Opus Genetics to create a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of inherited retinal diseases (IRDs). The combined company is trading on the Nasdaq under the ticker s

      10/25/24 12:00:00 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocuphire Pharma Announces Acquisition of Opus Genetics

      Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025 LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances remains on track for top-line data in Q1 2025 VEGA-3 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in presbyopia remains on track for top-line data in H1 2025 Company will seek a strategic partner to continue development of

      10/22/24 4:05:00 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

      FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced the publication of full results from two pivotal Phase 3 clinical trials (MIRA-2 and MIRA-3) that evaluated the safety and efficacy of RYZUMVI™ (Phentolamine Ophthalmic Solution 0.75%) for the treatment of pharmacologically-induced mydriasis in the peer-reviewed journal Ophthalmology. The results demonstrated that Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2

      9/30/24 8:00:00 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Graves Adrienne L

      4 - Opus Genetics, Inc. (0001228627) (Issuer)

      10/24/24 5:59:15 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bennett Jean was granted 100,000 shares (SEC Form 4)

      4 - Opus Genetics, Inc. (0001228627) (Issuer)

      10/24/24 5:56:44 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Yerxa Benjamin R

      3 - Opus Genetics, Inc. (0001228627) (Issuer)

      10/24/24 5:54:36 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUP
    Leadership Updates

    Live Leadership Updates

    See more
    • Ocuphire Pharma Strengthens Leadership Team with Key Appointments

      Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP) ("Ocuphire"), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today. George Magrath, M.D. M.B.A, M.S. CEO commented, "As the biology of Ref-

      2/14/24 8:00:00 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

      FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointment of Joseph (Joe) K. Schachle, M.B.A., into the newly created role of Chief Operating Officer, effective today. "Joe is a highly accomplished pharmaceutical executive, and we are thrilled to welcome him to Ocuphire as Chief Operating Officer," said Dr. George Magrath, CEO of Ocuphire. "His appointment is part of a broader strategic initiative to expand our senior team as we plan for adv

      11/27/23 8:00:00 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director

      FARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and member of the Board of Directors, effective today. Dr. Magrath succeeds Rick Rodgers, M.B.A., Interim Chief Executive Officer and President since April 2023. Mr. Rodgers will remain on the company's Board of Directors. "We are thrilled to have Dr. Magrath, a highly accomplished pharmaceutical executive with e

      11/1/23 8:05:00 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ocuphire Pharma Inc. (Amendment)

      SC 13G/A - Ocuphire Pharma, Inc. (0001228627) (Subject)

      2/14/23 3:23:38 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ocuphire Pharma Inc.

      SC 13G - Ocuphire Pharma, Inc. (0001228627) (Subject)

      5/17/22 4:37:11 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ocuphire Pharma Inc. (Amendment)

      SC 13G/A - Ocuphire Pharma, Inc. (0001228627) (Subject)

      2/14/22 4:10:04 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $OCUP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • HC Wainwright & Co. initiated coverage on Ocuphire Pharma with a new price target

      HC Wainwright & Co. initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $26.00

      11/24/21 6:08:44 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners initiated coverage on Ocuphire Pharma with a new price target

      Alliance Global Partners initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $25.00

      4/5/21 7:14:18 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JonesTrading initiated coverage on Ocuphire Pharma with a new price target

      JonesTrading initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $20.00

      3/29/21 7:30:43 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for RYZUMVI issued to OCUPHIRE PHARMA INC

      Submission status for OCUPHIRE PHARMA INC's drug RYZUMVI (ORIG-1) with active ingredient PHENTOLAMINE has changed to 'Approval' on 09/25/2023. Application Category: NDA, Application Number: 217064, Application Classification: Type 3 - New Dosage Form

      9/26/23 12:02:02 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care